No benefit from daratumumab, bortezomib and dexamethasone (D-Vd) in real-world patients with functional high-risk multiple myeloma: A report from the Myeloma and Related Diseases Registry
- Author(s)
- Lim, SL; Wellard, C; Rajagopal, R; Harrison, SJ; Khot, A; Quach, H; Ho, PJ; Moore, E; Wood, E; Spencer, A;
- Journal Title
- British Journal of Haematology
- Publication Type
- Online publication before print
- Keywords
- daratumumab; functional high‐risk disease; myeloma; real world; registry
- Department(s)
- Haematology
- Publisher's Version
- https://doi.org/10.1111/bjh.70238
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2026-01-08 02:25:14
Last Modified: 2026-01-08 02:25:33